Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 31, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification regarding share ownership changes within a specific employee fund and does not contain financial performance data.
Material Changes
The filing details a change in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan"). As a result of a fund movement on October 27, 2005, the holdings decreased from 18,344,636 to 18,326,595 shares. The average price for this transaction was $49.90.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the Plan is a discretionary fund for employees and former employees, and that Directors Dr. J.P. Garnier and Dr. T. Yamada are potentially interested in the shares held in the fund in the same manner as other beneficiaries.
Investor Verification Points
- Verify the impact of the share reduction (18,041 shares) on the total holdings of the US Retirement Savings Plan.
- Confirm the average transaction price of $49.90 against market data for October 27, 2005.
- Note that this filing does not reflect operational or financial performance for the period.